

Literatur für onkologie heute 11/2021

SCHWERPUNKT: Immunonkologie

CME: Immunonkologie in der Urologie – Ein Überblick über aktuelle Therapielinien und Perspektiven (S. 32–37)

J. Landmesser, J. Ring, A. S. Merseburger

1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nat Commun* 2020; 11: 3801
2. Robert C et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. *J Clin Oncol* 2018; 36: 1668–74
3. Heinzerling L et al. Checkpoint-Inhibitoren. *Dtsch Arztebl Int* 2019; 116: 119–26
4. Hoffman-Censits JH et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). *J Clin Oncol* 2016; 34: 355
5. Vuky J et al. Long-Term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. *J Clin Oncol* 2020; 38: 2658–66
6. Galsky MD et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2020; 395: 1547–57
7. Powles T et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2021; 22(7): 931–45
8. Powles T et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol* 2020; 21: 1574–88
9. Powles T et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *N Engl J Med* 2020; 383: 1218–30
10. Powles T et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2018; 391: 748–57
11. Fradet Y et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. *Ann Oncol* 2019; 30: 970–76
12. Sharma P et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2017; 18: 312–22
13. Powles T et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma. *JAMA Oncol* 2017; 3: e172411
14. Retz M, Maisch P, Gschwend JE. S3-Leitlinie Harnblasenkarzinom. *Urologe* 2016; 55: 1188–91
15. Powles T et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. *N Engl J Med* 2021; 384: 1125–35

16. Bellmunt J et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2021; 22: 525–37
 17. Bajorin DF et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). *J Clin Oncol* 2021; 39: 391
 18. Motzer RJ et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015; 373: 1803–13
 19. Motzer RJ et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med* 2018; 378: 1277–90
 20. Onkologie Leitlinienprogramm. S3-Leitlinie Nierenzellkarzinom. 2017. 1–219
 21. Rini BI et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2019; 380: 1116–12
 22. Motzer RJ et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2019; 380: 1103–15
 23. Choueiri TK et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2021; 384: 829–41
 24. Motzer RJ et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). *J Clin Oncol* 2021; 39: 269
 25. Beer TM et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. *J Clin Oncol* 2017; 35: 40–7
-